Creating Next-Generation CHO Expression Platforms Through Application of Omics Technologies

Chinese hamster ovary (CHO)-based biomanufacturing platforms have transformed the industrial production of biologics such as monoclonal antibodies (mAbs) over the last few decades, and despite advances in alternative expression systems (E. coli, yeast, etc.), the dominance of the CHO platform looks set to continue. As the therapeutic protein landscape continues to evolve, the fundamental requirements of a manufacturing process remain consistent – for an economically-viable CHO-based bioprocess, we need stable high titres of product obtained with controlled product quality (PQ). But the next-generation of CHO-based bioproduction platforms will have to contend with a wider and more diverse set of challenges, and so it’s worth considering what technologies we have at our disposal to meet these demands.

In this article, we will consider how omics technologies can be used to create improved expression platforms, and peer further into the future to see where the application of predictive tools linked to omics datasets may potentially create truly transformative expression solutions.